Tjoapack secures investment to increase pharma packaging capabilities
.jpg)
The CPO has immediate plans to expand its automated packaging capabilities, including for injectable products.
Tjoapack Netherlands, a global contract packaging organisation (CPO) for the pharmaceutical industry, has secured investment that will enable it to expand capabilities to meet growing industry demand for high-quality pharmaceutical packaging services across different dosage forms.
Tjoapack has immediate plans to invest in expanding its automated packaging capabilities, including for injectable products, allowing the company to cater to market demand for pre-filled syringes and vial packaging.
Last year, the CPO decided to seek investment from a strong financial partner with experience in the industry to help it to achieve its long-term strategic goals. They found that partner in Ampersand Capital Partners, a private equity firm that specialises in partnering with entrepreneur-led healthcare companies.
In conjunction with the deal, Dexter Tjoa, Tjoapack’s Director of Corporate Strategy has been appointed as CEO. Eric Tjoa, the company’s founder and previous CEO, will retain a seat on the Board of Directors.
Dexter Tjoa said: “We are committed to shaping the future of the pharmaceutical supply chain and meeting the ever-changing demands of the industry. With that comes ensuring we have the capacity and capabilities to provide a comprehensive set of services to our global customer base.”
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.